Author

Christopher Gasink 1

1 Janssen Research & Developme

A POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN?S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 CLINICAL TRIAL PROGRAMS

Subrata Ghosh, Bruce E. Sands, Willem de Villiers, Elyssa Ott, Christopher Gasink, Yinghua Lang, Philippe Szapary, Douglas Jacobstein, Brian G. Feagan

Association of Ustekinumab Serum Concentrations and Perianal Fistula Resolution in the Crohn's Disease UNITI Program

Bruce E. Sands, Brian Kramer, Christopher Gasink, Douglas Jacobstein, Long-Long Gao, Tony Ma, Omoniyi J. Adedokun, Jean-Frederic Colombel, David A Schwartz

DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90 MG Q8W IN PHASE III PROGRAM

Dominik Naessens, Jewel Johanns, Christopher Gasink

EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE ?SEVERE CROHN?S DISEASE PATIENTS: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY

Bruce E. Sands, Christopher Gasink, Douglas Jacobstein, Long Long Gao, Jewel Johanns, Philippe Szapary, Jean-Frederic Colombel, Stephan Targan, Subrata Ghosh, William Sandborn

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION

William Sandborn, Paul Rutgeerts, John Lynch, Rory Rebuck, Yuhua Wang, Bin Zou, Christopher Gasink, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B Hanauer, Stephan Targan, Subrata Ghosh, Willem de Villiers, Jean-Frederic Colombel, Brian G. Feagan

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 3 YEARS

William Sandborn, Paul Rutgeerts, Douglas Jacobstein, Christopher Gasink, Rishit Patel, Bin Zou, Jewel Johanns, Bruce E. Sands, Stephen B Hanauer, Stephan Targan, Subrata Ghosh, Willem de Villiers, Jean-Frederic Colombel, Brian G. Feagan

EFFICACY OF USTEKINUMAB FOR INDUCTION AND MAINTENANCE OF ENDOSCOPIC HEALING IN PATIENTS WITH CROHN?S DISEASE

Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Stephen B Hanauer, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary, Brian G. Feagan, William Sandborn

EXPOSURE-RESPONSE TO SC USTEKINUMAB IN MODERATE –SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY

Omoniyi J. Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long-Long Gao, Hugh M Davis, Steve Hanauer, Brian G. Feagan, Subrata Ghosh, William Sandborn

Identification of risk factors associated with loss of response to ustekinumab in Crohn's disease

Stephen B Hanauer, Bruce E. Sands, Brian G. Feagan, A Oortwijn, Roger van Kruchten, Victor Laliman, James Izanec, Omoniyi J. Adedokun, Long-Long Gao, Sheldon Sloan, Christopher Gasink, S Targan, Willem de Villiers, Paul Rutgeerts, Jean-Frederic Colombel, Subrata Ghosh

Immunogenicity of Ustekinumab in Patients with Crohn's Disease: Results from the IM-UNITI Study

William Sandborn, Bruce E. Sands, Jeannette Nussbaum, A Oortwijn, Christopher Gasink, Douglas Jacobstein, Long-Long Gao, Omoniyi J. Adekokun, Willem de Villiers, Subrata Ghosh

Item 1 - 10 / 15
1
2